Alpha Cognition to Showcase ZUNVEYL Data at Key Alzheimer’s Conferences

Event summary

  • Alpha Cognition will present new clinical data on ZUNVEYL at the AAGP (April 16-20, 2026) and NEI Spring Congress (May 1-3, 2026).
  • Four poster presentations will focus on ZUNVEYL’s clinical benefits, nursing home placement delays, psychotropic medication use, and therapy persistence in Alzheimer’s disease.
  • ZUNVEYL is an FDA-approved acetylcholinesterase inhibitor with a differentiated mechanism targeting nicotinic receptors.
  • Alpha Cognition is also developing ZUNVEYL in combination with memantine and as a sublingual formulation for cognitive impairment with mild traumatic brain injury (mTBI).

The big picture

Alpha Cognition’s presentation of new ZUNVEYL data comes at a time when the Alzheimer’s disease market is increasingly focused on cholinesterase inhibitors with differentiated mechanisms. The company’s strategy to highlight ZUNVEYL’s unique nicotinic receptor modulation could position it as a preferred option in a competitive landscape. The upcoming conference presentations will be critical in shaping physician and investor perceptions of ZUNVEYL’s clinical and commercial potential.

What we're watching

Clinical Validation
How the new data will position ZUNVEYL against existing treatments like donepezil and rivastigmine.
Market Adoption
Whether the differentiated mechanism of ZUNVEYL will drive prescriber preference and patient adherence.
Pipeline Progress
The pace at which Alpha Cognition advances ZUNVEYL’s combination therapy and sublingual formulation.